5 June 2026 - IntraBio Inc. today announced the submission of a variation application to the EMA to expand the approved marketing authorisation application for Aqneursa (levacetylleucine) to include the treatment of ataxia-telangiectasia.

This submission represents the first regulatory application submitted to the EMA seeking approval of a therapy for the treatment of ataxia-telangiectasia, a rare, progressive, inherited neurodegenerative disorder.

Read IntraBio press release